These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 30792169)

  • 21. [Research progress of iron metabolism in phenotype modification of β-thalassemia].
    Chen D; Sun X
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2021 Jan; 38(1):27-31. PubMed ID: 33423253
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New Insights Into Pathophysiology of β-Thalassemia.
    Sanchez-Villalobos M; Blanquer M; Moraleda JM; Salido EJ; Perez-Oliva AB
    Front Med (Lausanne); 2022; 9():880752. PubMed ID: 35492364
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improving Ineffective Erythropoiesis in Thalassemia: A Hope on the Horizon.
    Madan U; Bhasin H; Dewan P; Madan J
    Cureus; 2021 Oct; 13(10):e18502. PubMed ID: 34754662
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recent Progress in Gene Therapy and Other Targeted Therapeutic Approaches for Beta Thalassemia.
    Hamed EM; Meabed MH; Aly UF; Hussein RRS
    Curr Drug Targets; 2019; 20(16):1603-1623. PubMed ID: 31362654
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Morbidities in non-transfusion-dependent thalassemia.
    Saliba AN; Taher AT
    Ann N Y Acad Sci; 2016 Mar; 1368(1):82-94. PubMed ID: 27186941
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Iron metabolism and ineffective erythropoiesis in beta-thalassemia mouse models.
    Ramos P; Melchiori L; Gardenghi S; Van-Roijen N; Grady RW; Ginzburg Y; Rivella S
    Ann N Y Acad Sci; 2010 Aug; 1202():24-30. PubMed ID: 20712768
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interaction of Transfusion and Iron Chelation in Thalassemias.
    Porter JB; Garbowski MW
    Hematol Oncol Clin North Am; 2018 Apr; 32(2):247-259. PubMed ID: 29458730
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Thalassaemia.
    Taher AT; Weatherall DJ; Cappellini MD
    Lancet; 2018 Jan; 391(10116):155-167. PubMed ID: 28774421
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Iron overload across the spectrum of non-transfusion-dependent thalassaemias: role of erythropoiesis, splenectomy and transfusions.
    Porter JB; Cappellini MD; Kattamis A; Viprakasit V; Musallam KM; Zhu Z; Taher AT
    Br J Haematol; 2017 Jan; 176(2):288-299. PubMed ID: 27917462
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increasing prevalence of thalassemia in America: Implications for primary care.
    Sayani FA; Kwiatkowski JL
    Ann Med; 2015; 47(7):592-604. PubMed ID: 26541064
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Defining curative endpoints for transfusion-dependent β-thalassemia in the era of gene therapy and gene editing.
    Corbacioglu S; Frangoul H; Locatelli F; Hobbs W; Walters M
    Am J Hematol; 2024 Mar; 99(3):422-429. PubMed ID: 38100154
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cellular and animal models for the investigation of β-thalassemia.
    Nai A; Cordero-Sanchez C; Tanzi E; Pagani A; Silvestri L; Di Modica SM
    Blood Cells Mol Dis; 2024 Jan; 104():102761. PubMed ID: 37271682
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [γ-Globin Inductive Therapy of β-thalassemia and Its Relationship with MicroRNA].
    Li YY; Gu J; Yu DN
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Apr; 24(2):627-31. PubMed ID: 27151042
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pathophysiology of beta thalassemia--a guide to molecular therapies.
    Thein SL
    Hematology Am Soc Hematol Educ Program; 2005; ():31-7. PubMed ID: 16304356
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardiac complications in thalassemia throughout the lifespan: Victories and challenges.
    Wood JC
    Ann N Y Acad Sci; 2023 Dec; 1530(1):64-73. PubMed ID: 37902424
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel therapies in β-thalassaemia.
    Grech L; Borg K; Borg J
    Br J Clin Pharmacol; 2022 Jun; 88(6):2509-2524. PubMed ID: 34004015
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thalassemia.
    Cohen AR; Galanello R; Pennell DJ; Cunningham MJ; Vichinsky E
    Hematology Am Soc Hematol Educ Program; 2004; ():14-34. PubMed ID: 15561674
    [TBL] [Abstract][Full Text] [Related]  

  • 38. mRNA expression of iron regulatory genes in beta-thalassemia intermedia and beta-thalassemia major mouse models.
    Weizer-Stern O; Adamsky K; Amariglio N; Rachmilewitz E; Breda L; Rivella S; Rechavi G
    Am J Hematol; 2006 Jul; 81(7):479-83. PubMed ID: 16755567
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Beyond transfusion therapy: new therapies in thalassemia including drugs, alternate donor transplant, and gene therapy.
    Porter J
    Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):361-370. PubMed ID: 30504333
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Current management of thalassemia intermedia].
    Thuret I
    Transfus Clin Biol; 2014 Nov; 21(4-5):143-9. PubMed ID: 25282488
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.